Global View: What should investors do with Maruti Suzuki, L&T and IPCA Laboratories?

The Indian markets bounced back on Wednesday after slipping below the crucial support levels in the previous session.

We have collated a list of recommendations from various global brokerage firms according to a Zee Business TV report:

See Zee Business Live TV Streaming Below:

Maruti Suzuki

Goldman Sachs: Buy Rating | Target Price Rs 9000

Goldman Sachs maintained its buy rating on Maruti Suzuki with a target price of Rs 9000 that translates into an upside of over 11 per cent from Rs 8049 recorded on 16 November.

The chip supply improvement and capacity addition are some of the factors that are in focus. The automaker is better placed in the current situation, given higher exposure to entry-level vehicles.

L&T

CLSA: Buy Rating | Target Price Rs 2250

CLSA maintained its buy rating on L&T with a target price of Rs 2250 that translates into an upside of over 15 per cent from Rs 1955 recorded on 16 November.

The global investment bank is upbeat on infrastructure capex, and the guidance is on track and divestment as well, but some delays are possible.
 
CLSA is confident on margins, and we look out for five-year plan, said the note.

IPCA Laboratories

Jefferies: Buy Rating | Target Price Rs 2477

Jefferies maintained its buy rating on IPCA Laboratories and raised its target price to Rs 2477 from Rs 2945 earlier.

The 2Q revenue was largely in line but EBITDA/PAT 8%/15% was below estimates. The domestic business remains strong, and the outlook remains upbeat.
 
Europe generics sales are struggling due to Covid disruption & high distributor inventory FY22/23 EPS decline by 15%/7%.

(Disclaimer: The views/suggestions/advices expressed here in this article is solely by investment experts. Zee Business suggests its readers to consult with their investment advisers before making any financial decision.)